资料显示，深圳迈瑞生物医疗电子股份有限公司位于广东省深圳市南山区高新技术产业园区科技南十二 路迈瑞大厦1-4层，成立日期1999年1月25日，上市日期2018年10月16日，公司主营业务涉及医疗器械的 研发、制造、营销及服务。主营业务收入构成为：体外诊断类产品38.37%，生命信息与支持类产品 32.73%，医学影像类产品19.78%，电生理与血管介入类产品7.25%，其他产品1.56%，其他(补 充)0.31%。 迈瑞医疗所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：血氧仪、智慧医疗、体 外诊断、医疗器械、融资融券等。 10月10日，迈瑞医疗盘中下跌2.00%，截至10:59，报243.27元/股，成交9.22亿元，换手率0.31%，总市 值2949.51亿元。 资金流向方面，主力资金净流入2472.10万元，特大单买入1.11亿元，占比12.00%，卖出1.02亿元，占比 11.11%；大单买入2.46亿元，占比26.69%，卖出2.30亿元，占比24.90%。 迈瑞医疗今年以来股价跌3.36%，近5个交易日跌0.71%，近20日涨4.77%，近60日涨11.93%。 分红方面，迈瑞医疗 ...

Core Viewpoint - Mindray Medical experienced a stock price increase of 2.03% on September 30, reaching 243.86 CNY per share, with a total market capitalization of 295.67 billion CNY [1] Financial Performance - For the first half of 2025, Mindray Medical reported a revenue of 16.743 billion CNY, a year-on-year decrease of 18.45%, and a net profit attributable to shareholders of 5.069 billion CNY, down 32.96% year-on-year [2] - Since its A-share listing, Mindray Medical has distributed a total of 33.699 billion CNY in dividends, with 23.388 billion CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for Mindray Medical was 91,600, a decrease of 0.68% from the previous period, with an average of 13,241 circulating shares per person, an increase of 0.69% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, holding 131 million shares, a decrease of 3.0252 million shares from the previous period [3]

Core Points - The stock price of Mindray Medical has decreased by 4.62% year-to-date, with a recent increase of 2.17% over the last five trading days [2] - As of June 30, 2025, Mindray Medical reported a revenue of 16.743 billion yuan, a year-on-year decrease of 18.45%, and a net profit of 5.069 billion yuan, down 32.96% year-on-year [2] - The company has distributed a total of 33.699 billion yuan in dividends since its A-share listing, with 23.388 billion yuan distributed in the last three years [3] Company Overview - Mindray Medical, established on January 25, 1999, and listed on October 16, 2018, is located in Shenzhen, Guangdong Province, and specializes in the research, manufacturing, marketing, and service of medical devices [2] - The company's main business revenue composition includes: in vitro diagnostic products (38.37%), life information and support products (32.73%), medical imaging products (19.78%), electrophysiology and vascular intervention products (7.25%), and other products (1.56%) [2] Shareholder Information - As of June 30, 2025, the number of shareholders for Mindray Medical was 91,600, a decrease of 0.68% from the previous period [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 131 million shares, a decrease of 3.0252 million shares from the previous period [3]

9月25日，迈瑞医疗盘中上涨2.01%，截至11:20，报238.60元/股，成交12.90亿元，换手率0.45%，总市 值2892.89亿元。 截至6月30日，迈瑞医疗股东户数9.16万，较上期减少0.68%；人均流通股13241股，较上期增加0.69%。 2025年1月-6月，迈瑞医疗实现营业收入167.43亿元，同比减少18.45%；归母净利润50.69亿元，同比减 少32.96%。 分红方面，迈瑞医疗A股上市后累计派现336.99亿元。近三年，累计派现233.88亿元。 机构持仓方面，截止2025年6月30日，迈瑞医疗十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股1.31亿股，相比上期减少302.52万股。易方达创业板ETF（159915）位居第五大流通股 东，持股1365.26万股，相比上期减少3.01万股。华宝中证医疗ETF（512170）位居第六大流通股东，持 股1101.24万股，相比上期增加88.93万股。华泰柏瑞沪深300ETF（510300）位居第七大流通股东，持股 1081.65万股，相比上期增加88.31万股。易方达沪深300医药ETF（512010）位居第八大流通股 ...

创新药行业的"BD时刻"已经来临，但医疗器械行业的东风还未吹起。 过去几年，医疗器械行业经历了一轮比较大的"挤泡沫"的过程，头部的医疗器械龙头几乎都遭到了惨烈 的估值杀。其中，就包括了医疗器械"一哥"迈瑞医疗。 随着集采的深入，迈瑞医疗的好日子也是一去不复返。 侃见财经根据其财报统计，2016年至2023年，迈瑞医疗年均营收保持着两位数的增速，营收从90.32亿 元一路暴涨至349.32亿元；净利润更是常年保持在20%的增速以上，年净利润也从16.00亿元一路暴涨至 115.82亿元。 伴随估值泡沫的破裂，迈瑞的业绩也遭到了很大的挑战。 根据财报显示，自2024年开始，迈瑞的营收增速就已经降至1%都不到了，其中扣非净利润也几乎零增 长。 在这种背景下，市场选择了用脚投票。 好在企业底子很厚，相比于同行，迈瑞医疗股价却表现出了一定的韧性。但如果从最高位计算，迈瑞医 疗股价也接近腰斩，根据统计显示，从年线来看，迈瑞医疗已经连跌五年，虽然2025年跌幅有所放缓， 但截至目前，其年内跌幅依旧超过了4%，大幅跑输医疗器械ETF。 股价的变化，影响最大的当属企业的实际控制人。受此影响，迈瑞医疗实际控制人李西廷、 徐航身家 ...

Company Overview - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. was established on January 25, 1999, and listed on October 16, 2018. The company is located in the High-tech Industrial Park, Nanshan District, Shenzhen, Guangdong Province. Its main business involves the research, manufacturing, marketing, and service of medical devices [1]. Financial Performance - As of June 30, 2025, Mindray Medical reported a revenue of 16.743 billion yuan, a year-on-year decrease of 18.45%. The net profit attributable to shareholders was 5.069 billion yuan, down 32.96% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 33.699 billion yuan, with 23.388 billion yuan distributed in the last three years [3]. Stock Market Activity - On September 4, 2023, Mindray Medical's stock price fell by 2.05%, closing at 233.92 yuan per share, with a trading volume of 1.417 billion yuan and a turnover rate of 0.49%. The total market capitalization was 283.614 billion yuan [1]. - Year-to-date, the stock price has decreased by 7.55%, with a 5-day decline of 5.33%, a 20-day increase of 1.36%, and a 60-day decrease of 1.13% [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders was 91,600, a decrease of 0.68% from the previous period. The average number of circulating shares per person increased by 0.69% to 13,241 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, holding 131 million shares (a decrease of 3.0252 million shares), and E Fund's various ETFs, with mixed changes in holdings [3]. Business Segmentation - The revenue composition of Mindray Medical includes: in vitro diagnostic products (38.37%), life information and support products (32.73%), medical imaging products (19.78%), electrophysiology and vascular intervention products (7.25%), and other products (1.56%) [1].

Core Viewpoint - The company reported a significant decline in revenue and net profit for the first half of 2025, attributed to cyclical adjustments in the domestic market, but anticipates recovery in the latter half of the year [1][3][10]. Financial Performance - The company achieved operating revenue of 16.743 billion yuan, a decrease of 18.45% year-on-year [2] - Net profit attributable to shareholders was 5.069 billion yuan, down 32.96% compared to the previous year [2] - The net cash flow from operating activities fell by 53.83% to 3.922 billion yuan [2] - Basic earnings per share decreased by 33% to 4.184 yuan [2] - Total assets increased by 3.76% to 58.775 billion yuan, while net assets attributable to shareholders rose by 8.88% to 39.041 billion yuan [2] Domestic Market Challenges - The decline in domestic performance is primarily due to a delayed bidding cycle and the impact of policy changes in the medical device market [3] - The company expects the negative effects of the bidding delays to gradually diminish in the second half of 2025, with a potential recovery in domestic business [3][10] International Business Growth - International business grew by 5.39% year-on-year, now accounting for approximately 50% of total revenue [4] - The international in-vitro diagnostics segment showed double-digit growth, with the chemiluminescence product line exceeding 20% growth [4] - The company is expanding its market share in high-end medical devices globally, which helps offset domestic declines [4][7] Business Segment Performance - All three main business segments (in-vitro diagnostics, life information and support, and medical imaging) experienced year-on-year declines, but with notable structural differences [5] - In-vitro diagnostics revenue was 6.424 billion yuan, down 16.11% [6] - Life information and support revenue was 5.479 billion yuan, down 31.59% [6] - Medical imaging revenue was 3.312 billion yuan, down 22.51% [6] R&D Investment - The company maintained high R&D investment, totaling 1.77 billion yuan, which is 10.61% of revenue [8] - The focus on AI and automation in product development aims to enhance competitiveness in high-end markets [8] Market and Industry Context - The report reflects the cyclical adjustments in the medical device industry, with short-term pressures from policy changes and competition, but long-term growth prospects remain strong [9] - The company is well-positioned in international markets, particularly in developing countries and high-end segments in Europe and the U.S. [9] Conclusion - The company's performance in the first half of 2025 indicates a phase of adjustment rather than decline, with expectations for recovery driven by international growth and ongoing R&D efforts [13]

Group 1 - The core viewpoint of the articles highlights that Mindray Medical's stock closed at 236.56 yuan, with a rolling PE ratio of 25.75 times and a total market capitalization of 286.815 billion yuan [1] - The average PE ratio for the medical device industry is 59.32 times, with a median of 39.97 times, positioning Mindray Medical at the 50th rank within the industry [1] - As of March 31, 2025, the number of shareholders for Mindray Medical increased to 92,191, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Mindray Medical's main business includes the research, manufacturing, marketing, and service of medical devices, with key products in life information and support, in vitro diagnostics, medical imaging, electrophysiology, and vascular intervention [1] - The latest quarterly report for Q1 2025 shows that the company achieved operating revenue of 8.237 billion yuan, a year-on-year decrease of 12.12%, and a net profit of 2.629 billion yuan, down 16.81% year-on-year, with a gross profit margin of 62.53% [1] - The PE ratios of other companies in the medical device industry range from 11.61 times for Ji'an Medical to 20.96 times for Antu Bio, with Mindray Medical's PE ratio being significantly lower than the industry average [2]

Group 1 - The core viewpoint of the articles highlights that Mindray Medical's stock closed at 234.18 yuan, down 1.04%, with a rolling PE ratio of 25.49 times and a total market capitalization of 283.93 billion yuan [1] - In comparison to the medical device industry, which has an average PE ratio of 59.49 times and a median of 40.19 times, Mindray Medical ranks 51st [1] - The net outflow of main funds for Mindray Medical on August 19 was 8.04 million yuan, with a total outflow of 7.57 million yuan over the past five days [1] Group 2 - Mindray Medical's main business includes the research, manufacturing, marketing, and service of medical devices, with key products in life information and support, in vitro diagnostics, medical imaging, electrophysiology, and vascular intervention [1] - The latest quarterly report for Q1 2025 shows that the company achieved operating revenue of 8.24 billion yuan, a year-on-year decrease of 12.12%, and a net profit of 2.63 billion yuan, down 16.81%, with a gross profit margin of 62.53% [1] - The PE ratios for Mindray Medical are 25.49 (TTM) and 24.33 (static), with a price-to-book ratio of 7.36 [2]

8月7日，迈瑞医疗今日收盘230.79元，上涨1.09%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到25.12倍，总市值2798.19亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入82.37亿元，同比-12.12%；净利润26.29亿元，同 比-16.81%，销售毛利率62.53%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13迈瑞医疗25.1223.987.252798.19亿行业平均 54.7951.294.80116.92亿行业中值37.8638.002.7755.22亿1九安医疗11.1511.280.88188.19亿2英科医疗 15.9217.161.42251.53亿3新华医疗16.1314.951.32103.38亿4振德医疗16.1915.261.0358.78亿5山东药玻 16.2416.291.87153.63亿6奥美医疗16.7216.391.7260.41亿7康德莱17.6917.711.4738.13亿8维力医疗 17.7518.972.2341.62亿9九强生物17.8316.582.1888.30亿10奥泰生物18.5619.571 ...